SCHEMBL8375577

SCHEMBL8375577

CC(C)(C)OC(=O)OC(=O)OC(C)(C)C.CC(C)(C)OC(=O)OC(=O)OC(C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 1/20 0.42
ELANE P08246 1/20 0.41
USP2 O75604 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HDAC6 Q9UBN7 2/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC2 Q92769 1/20 0.38
SOAT1 P35610 1/20 0.36
ALDH1A1 P00352 3/20 0.33
TDP1 Q9NUW8 1/20 0.32
TSHR P16473 2/20 0.32
HPGD P15428 1/20 0.31
CHRM2 P08172 1/20 0.31
CHRM1 P11229 1/20 0.31
CHRM3 P20309 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
CA7 P43166 1/20 0.31
GAA P10253 2/20 0.31
MEN1 O00255 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5452 1.00 DGAT1 (0.42) DGAT1ELANEUSP2SMN1; SMN2HDAC6
SCHEMBL1145251 0.97 DGAT1 (0.40) DGAT1ELANEUSP2SMN1; SMN2HDAC6
SCHEMBL28072361 0.97 DGAT1 (0.40) DGAT1ELANEUSP2SMN1; SMN2HDAC6
SCHEMBL28239854 0.97 DGAT1 (0.40) DGAT1ELANEUSP2SMN1; SMN2HDAC6
SCHEMBL29482425 0.97 DGAT1 (0.40) DGAT1ELANEUSP2SMN1; SMN2HDAC6
SCHEMBL31469549 0.97 DGAT1 (0.40) DGAT1ELANEUSP2SMN1; SMN2HDAC6
SCHEMBL29808062 0.97 DGAT1 (0.40) DGAT1ELANEUSP2SMN1; SMN2HDAC6
Hydrochloric Acid SCHEMBL28367906 0.97 DGAT1 (0.40) DGAT1ELANEUSP2SMN1; SMN2HDAC6
SCHEMBL29740062 0.97 DGAT1 (0.40) DGAT1ELANEUSP2SMN1; SMN2HDAC6
Ammonia Solution, Strong SCHEMBL28101892 0.97 DGAT1 (0.40) DGAT1ELANEUSP2SMN1; SMN2HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4704142-A1 LAMINATE, METHOD FOR MANUFACTURING LAMINATE, AND METHOD FOR MANUFACTURING SEMICONDUCTOR DEVICE Toray Industries, Inc. (JP) 2026-03-04 EP disclosed
US-12534399-B2 Laminate and manufacturing method of semiconductor device TORAY INDUSTRIES, INC. (JP) 2026-01-27 US disclosed
US-20250361224-A1 PYRIMIDINE COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2025-11-27 US disclosed
WO-2024225363-A1 LAMINATE, METHOD FOR MANUFACTURING LAMINATE, AND METHOD FOR MANUFACTURING SEMICONDUCTOR DEVICE 東レ株式会社 2024-10-31 WO disclosed
WO-2024203435-A1 METHOD FOR PRODUCING TRANSFER LAMINATE, TRANSFER LAMINATE, AND SEMICONDUCTOR DEVICE PRODUCTION METHOD 東レ株式会社 2024-10-03 WO disclosed
US-12060457-B2 Resin composition for display substrate, resin film for display substrate and laminate body containing this, image display device, organic EL display, and manufacturing method of these TORAY INDUSTRIES, INC. (JP) 2024-08-13 US disclosed
US-20240186172-A1 LAMINATE, RESIN COMPOSITION, AND METHOD FOR MANUFACTURING SEMICONDUCTOR DEVICE TORAY INDUSTRIES, INC. (JP) 2024-06-06 US disclosed
US-20240166556-A1 LAMINATE AND MANUFACTURING METHOD OF SEMICONDUCTOR DEVICE TORAY INDUSTRIES, INC. (JP) 2024-05-23 US disclosed
CN-114341270-B Resin film, electronic device, method for producing resin film, and method for producing electronic device 东丽株式会社 2024-03-08 CN disclosed
EP-4316815-A1 LAMINATE AND MANUFACTURING METHOD OF SEMICONDUCTOR DEVICE Toray Industries, Inc. (JP) 2024-02-07 EP disclosed
CN-113474156-B Polyamic acid resin composition, polyimide resin film and method for producing same, laminate, and electronic device and method for producing same 东丽株式会社 2022-04-29 CN disclosed
CN-114341270-A Resin film, electronic device, method for producing resin film, and method for producing electronic device 东丽株式会社 2022-04-12 CN disclosed
US-20200383993-A1 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE ARENA PHARMACEUTICALS, INC. 2020-12-10 US disclosed
US-10624900-B2 5-HT2C receptor agonists and compositions and methods of use ARENA PHARMACEUTICALS, INC. (US) 2020-04-21 US disclosed
US-20200078368-A1 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE ARENA PHARMACEUTICALS, INC. 2020-03-12 US disclosed
US-10272094-B2 5-HT2C receptor agonists and compositions and methods of use ARENA PHARMACEUTICALS, INC. (US) 2019-04-30 US disclosed
US-20180214455-A1 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE ARENA PHARMACEUTICALS, INC. 2018-08-02 US disclosed
CN-106794181-A MTH1 inhibitors for the treatment of inflammatory and autoimmune conditions 托马斯·黑勒戴药物研究基金会 2017-05-31 CN disclosed
US-5879852-A POLYMERIC BINDER HAVING ACID-LABILE GROUPS AGFA-GEVAERT AG (DE) 1999-03-09 US disclosed
US-5654121-A A HYDROXY- OR ESTER-CONTAINING STYRENE-BASED POLYMER HAVING ACID-LABILE GROUPS AND A PHOTOSENSITIVE COMPOUND RELEASING A STRONG ACID UPON IRRADIATION; STORAGE STABILITY; HEAT RESISTANCE; LOW DARK EROSION; PRINTING PLATES; PHOTORESISTS AGFA-GEVAERT AG (DE) 1997-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250361224-A1 PYRIMIDINE COMPOUND UMPS, TPMT, TYMS DGAT1 2746/4885ELANE 4319/4885USP2 4343/4885
US-10624900-B2 5-HT2C receptor agonists and compositions and methods of use HTR2C, HTR2A, HCRTR2 DGAT1 3333/4885ELANE 3188/4885USP2 2815/4885
US-20180214455-A1 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE HTR2C, HTR2A, HCRTR2 DGAT1 3333/4885ELANE 3188/4885USP2 2815/4885
US-20200078368-A1 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE HTR2C, HTR2A, HCRTR2 DGAT1 3333/4885ELANE 3188/4885USP2 2815/4885
US-10272094-B2 5-HT2C receptor agonists and compositions and methods of use HTR2C, HTR2A, HCRTR2 DGAT1 3333/4885ELANE 3188/4885USP2 2815/4885
US-20200383993-A1 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE HTR2C, HTR2A, HCRTR2 DGAT1 3333/4885ELANE 3188/4885USP2 2815/4885
US-12534399-B2 Laminate and manufacturing method of semiconductor device LCP1, CDH1, L1CAM DGAT1 3135/4885ELANE 3399/4885USP2 2320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.